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Background: Extra-Corporeal Membrane Oxygenation (ECMO) therapy is associated with high risk of neurologic injury.
But the mechanism of neurologic injury during and/or after ECMO therapy is still unclear. Recent animal experiments
confirmed that ECMO treatment increases the immune inflammatory response. The aim of this study is to investigate
the effect of VV- ECMO on immune inflammatory response of cerebral tissues and neurological impairment.
Methods: 18 porcine were randomly divided into control, sham and ECMO group (n = 6/group). ECMO was run 24 h
in the ECMO group, and serum collected at 0, 2, 6, 12 and 24 h during ECMO treatment for the analysis of cytokine
(IL-1β, IL-6, IL-10, TNF-a) and cerebral injury specific biomarker S100B and NSE. After 24 h ECMO treatment, all animals
were euthanized and cerebral tissues (hypothalamus, hippocampus and cortex) were collected for measure of mRNA
and protein levels of cytokine (IL-1β, IL-6, IL-10, TNF-a).
Results: The results during ECMO treatment showed that all the pro-inflammation cytokines were increased
significantly after 2 h, and anti-inflammation IL-10 showed transient hoist in the first 2 h in serum. After 24 h ECMO
therapy, the mRNA levels of pro-inflammation cytokines and anti-inflammation IL-10 were simultaneously up-regulated
in cerebral tissues (hypothalamus, hippocampus and cortex). And protein concentrations also showed different
increasing levels in cerebral tissues. However, during the ECMO treatment, S100B and NSE protein in serum did not
change significantly.
Conclusion: These findings suggest VV-ECMO treatment can not only lead to immune inflammatory response in
blood, but can also produce immune and inflammatory response in cerebral tissues. However the extent of immune
inflammation was not sufficient to cause significant neurological impairment in this study. But the correlation between
cerebral inflammatory response and cerebral impairment need to further explore.
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Since 1972, when Extra-Corporeal Membrane Oxyge-
nation (ECMO) was, for the first time, reported as therapy
for adult respiratory distress syndrome (ARDS) successfully
[1], ECMO has been considered as an effective means of
treatment for the severe ARDS patients, and the success
rate is between 53 to 76% [2-5]. In ARDS patients, 70-
100% of survivors exhibit a distinctive neurological im-
pairment [6,7]. Hypoxia and immune inflammatory re-
sponse is a key factor for ARDS patients’ neurological
impairment [6,7]. Therefore, in theory, ECMO possibly
improves cerebral dysfunction in ARDS patients by in-
creasing oxygen supply to cerebral tissues. The recent
ECMO therapy’s successful application to cardiopulmo-
nary and brain resuscitation procedures proved that it
may have a protective effect on brain function [8].
However, ECMO therapy is associated with high risk
of neurologic injury. Poor neurologic outcomes have
been reported in as many as 10- 60% of survivors [9-11].
But the mechanism of neurologic injury during and/or
after ECMO therapy is still unclear. More recent animal
experiments confirmed that after two hours of ECMO
treatment, blood and tissues (liver, lung, intestinal and
renal) inflammatory cytokines’ (IL-1β, IL-6, IL-8, TNF-a)
expression was significantly increased [12]. Another ex-
perimental study showed that ECMO treatment can lead
to damage of the intestinal mucosal barrier, bacterial
translocation, and increased systemic immune inflamma-
tory response [13]. However, it is uncertain whether
ECMO treatment can lead to immune inflammatory
response as peripheral in cerebral tissues.
Once these inflammatory cytokines are produced in
the brain, or if there is a high expression of these inflam-
matory cytokines in the brain itself, they will damage the
cerebral tissues. For example, this can lead to nerve cell
apoptosis and necrosis [14,15], glial cells, neurons,
axonal injury, and brain tissue edema [16,17], neuro-
transmitter transporter obstacles [18], the destruction of
the blood–brain barrier [15]and increased oxidative
stress injury of the brain tissue [19]and so on. This may
be disastrous for ARDS patients. Therefore, in this study,
the effect of the venovenous (V-V) ECMO therapy on
cerebral tissues’ immune inflammatory response will be
explored and we will further investigate whether the im-
mune inflammatory response can cause neurologic in-
jury by normal porcine model.
Methods
Animal preparation
This study was approved by the Animal Care Committee
of Jingling Hospital. Twelve piglets of either sex weighed
(30.1 ± 2.8) kg. Before induction of anesthesia, the animals re-
ceived ketamine (20 mg/kgIM), diazepam (8 mg/kgIM), and
atropine (0.1 mg/kg IM). Later ketamine (10-20 mg/kg/hr IV)and diazepam (8 mg/kg/hr IV) were infused to main-
tain anesthesia.
Mechanical ventilation strategy
After performing tracheotomy and placing an internal
diameter 6.0-cm tracheal tube, mechanical ventilation
was established using volume-controlled mode with an
FIO2 of 0.21 and the positive end-expiratory pressure was
set at 5 mmHg.Tidal volumes were adjusted to 5-8 mL/kg
at 15 breath/min.
Establishment of the catheter and grouping
A 16G venous catheter was placed into the left internal
jugular vein to administer Ringer’s lactate at a rate of
3 ml/kg/hr initially. The rate was increased to maintain
the mean arterial pressure above 60 mmHg. A 16G catheter
was positioned into the right femoral artery to monitor
blood pressure.
After baseline measurements, animals were randomly
divided into three groups: Control group, Sham group
(to verify whether the required ECMO operative proce-
dure affected the results) and ECMO group (VV-ECMO,
n = 6/group). After heparin (150 U/kg IV) was given as
a bolus to the sham and ECMO groups, a 14F
Biomedicus venous drainage cannula (MedtronicPerfusion
Systems, Minneapolis, MN) was inserted into the right
femoral vein. Another 14F Biomedicus arterial cannula
(MedtronicPerfusion Systems, Minneapolis, MN) was
used for venous infusion and inserted into the internal
jugular vein. Heparin was infused to keep the whole blood
activated clotting time (ACT) at 180-220 s. Placement of
cannula was confirmed by ultrasonograph.
Experimental protocol
In the sham group, the vascular venous cannula was oc-
cluded at 0 hour. The VV-ECMO was established at 0
hour. VV-ECMO procedure is as follows: The ECMO
circuit (Quadrox PLS, Maquet, Germany) was primed
with 500 ml Voluven and 200-300 ml Ringer’s lactate.
The venovenous-ECMO system consisted of a centrifu-
gal pump (Rota flow Console, Maquet, Germany), and a
heat exchanger (Heater-Cooler Unit HCU 30, Maquet,
Germany) maintaining temperature at 37°C. Sweep gas
was 100% oxygen at a flow rate equal to the blood flow
rate (1:1). Blood in the circuit was drained from the right
femoral vein and infused into the right internal jugular
vein at the rate of 50 ml/kg-1min-1.
Sample collection
Blood samples (at 0, 2, 6, 12, 24 hours during ECMO
running) were collected from the right femoral artery for
measurement of TNF-a, IL-1beta, IL-6, IL-10, S100B
and NSE. Blood serum was centrifuged at 2500 rpm for
15 min at 4°C, and the serum was stored at −70°C.
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were euthanized with a bolus injection of potassium
chloride (40 ml, 0.1 g/ml) at 24 hours of ECMO treat-
ment. Frontal cortex, hippocampus, and hypothalamus
were dissected on ice. All brain regions were extracted
in 1 mL extraction buffer/100 mg tissue. Cerebral tissue
samples were homogenized in an ice-cold lysis buffer
containing 137 mM NaCl, 20 mM Tris – HCl (pH 8.0),
1% NP40, 10% glycerol, 1 mM PMSF 10 μ g/mL aprotinin,
1 μ g/mL leupetin, and 0.5 mM sodium vanadate. The tis-
sue homogenate solutions were centrifuged with 14000 × g
for 25 min at 4°C. The supernatants were collected and
stored at − 80°C until analysis.
Measurement of protein levels of cytokines, S100B and
NSE in serum and cerebral tissues
Quantification of serum and cerebral tissues TNF-a, IL-
1beta, IL-6, IL-10, S100B and NSE protein levels were
assessed by ELISA kit (R&D Systems, Munich, Germany),
according to manufacturer’s instructions. Cytokine results,
reported as pg/mL of serum or per gram of tissue (pg/g)
were expressed as mean values ± SD. Where indicated,
cytokine amounts were also normalized to protein con-
tent. In this case, the cytokine concentration of total pro-
tein in the brain extracts was measured by Bradford assay
(BioRad Laboratories). S100B and NSE reported as μg/L
were expressed as mean values ± SD.
Real-time PCR RNA preparation and analysis of
expression of cytokine genes in cerebral tissues
At 24 h ECMO treatment, frontal cortex, hippocampus,
and hypothalamus were collected and stored at − 80°C
until analysis. The total RNA from the sorted cerebral
tissues was isolated using Trizol reagent. Once isolated,
5 μg of total RNA was reverse transcribed to yield
cDNA. For each sample, 1 μl cDNA was added to a 50 μl
PCR containing 0.5 μl primer, 8 μl SYBR green I premix
and 11.3 μl ddH2O. The PCR temperature profile
consisted of a single cycle at 95°C for 10 min; 40 cycles for
15 s at 95°C, for 15 s at 60°C, and for 20 s at 72°C (exten-
sion), and a final cycle at 72°C for 2 min. Real-time quanti-
tative PCR was performed using a Rotor Gene 3000
system (Corbet, Australia). Gene expression was analyzed
using the Rotor-Gene Real-Time Analysis Software 6.1.
GAPDH was used as an internal control gene in order to





IL-10 5’- TGCCCCACATGCTCCGGGAA-3reverse transcription reactions. The primer sequences are
shown in Table 1.
Results
TNF-a, IL-1β, IL-6 and IL-10 proteins concentrations in
serum (Figure 1)
Compared with the control group, the inflammatory
cytokines (TNF-a, IL-1β, IL-6 and IL-10) did not show
significant change in the sham operation group (at each
time point, P > 0.05). After 2 h ECMO therapy, the num-
ber of pro-inflammatory cytokines TNF-a, IL-1β and IL-6
in the ECMO group was significantly higher than that of
control group. Anti-inflammatory cytokine IL-10 showed
a transient raise in the first two hours after ECMO treat-
ment, and then decreased to normal levels gradually.
TNF-a, IL-1β, IL-6 and IL-10 proteins concentrations in
cerebral tissues (Figure 2)
There was no statistical difference between the control
and sham groups (p > 0.05). After 24 h ECMO treat-
ment, pro-inflammation cytokine IL-1β, IL-6, TNF-a,
and anti-inflammation cytokine IL-10 protein concentra-
tions in the hypothalamus were notably higher than
those of the control group (p < 0.05). Although there
was no change in the hippocampus IL-1βprotein con-
centrations in the control and ECMO groups (p > 0.05),
the IL-6, IL-10 and TNF-a showed a substantial increase
(p < 0.05). In the cortex region, only IL-1βprotein con-
centrations were higher than that of the control group
(p < 0.05).
TNF-a, IL-1β, IL-6 and IL-10 mRNA expression in cerebral
tissues (Figure 3)
There was no statistical difference between the control
and sham groups (p > 0.05). After ECMO treatment, all
the cytokine expression of mRNA showed a significant
up-regulation compared with the control group in the
three brain regions.
S100B and NSE concentrations proteins in serum
(Figure 4)
There was no statistical difference between the control
and sham groups for S100B and NSE (p > 0.05). During
ECMO treatment, S100B and NSE protein increased
slightly, but there was no statistical difference between



























































































Figure 1 Effects of ECMO therapy on cytokine (IL-1, IL-6, IL-10 and TNF-a) in serum. The levels of cytokine (IL-1, IL-6, IL-10 and TNF-a) were
assessed 0, 2 6, 12 and 24 hours post-ECMO treatment by using specific ELISA. Results are reported as histograms representing the cytokine mean












































































Figure 2 Effects of ECMO therapy on cerebral tissues expression of cytokines at 24 hour’s post-ECMO treatment. The levels of cytokine
(IL-1, IL-6, IL-10 and TNF-a) were assessed 24 hours post-ECMO treatment by using specific ELISA, as described in the Methods section. Results are
reported as histograms representing the cytokine mean concentrations with SD. Asterisks inside the graphs indicate the significance of comparison
with control group: *P < 0.05.


















































































Figure 3 Effects of ECMO therapy on cerebral tissues mRNA expression of cytokines after 24 hour’s ECMO treatment. The mRNA levels
of cytokine (IL-1, IL-6, IL-10 and TNF-a) were assessed 24 hours post-ECMO treatment by Real-time PCR, as described in the Methods section.
Results are reported as histograms representing the cytokine mRNA mean levels with SD. Asterisks inside the graphs indicate the significance of
comparison with control group: *P < 0.05, **P < 0.01.
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ECMO has been considered an effective means of ther-
apy for the severe ARDS patients, and the efficiency rate
has been between 53 and 76% [2-5]. Hypoxia is the main
pathophysiological and physiological characteristic of
ARDS that causes systemic organ injury. So ECMO ther-
apy possibly improves high incidence of cerebral dys-
function in ARDS patients (70-100%) by increasing the
oxygen supply to the brain tissue, which is most sensi-
tive to hypoxia, theoretically. The recent successful ap-
plication of ECMO therapy to cardiopulmonary and
brain resuscitation procedures have proved that it may


























Figure 4 Effects of ECMO therapy on S100B and NSE in serum. The le
treatment by using specific ELISA. Results are reported as histograms repreHowever, ECMO is associated with high risk of neuro-
logic injury. Poor neurologic outcomes have been
reported in as many as 10-60% of survivors [9]. The
study reported that 58% patients developed clinical
neurological syndrome including epilepsy, fatigue, patho-
logical pupil and postpone sober [20], neuropsycho-
logical disorders and movement disorders [20], cerebral
edema [20] and brain atrophy [10], 52% showed symp-
toms of neuroimaging abnormalities, and 41% of EEG
abnormalities [11]. The mechanism of neurologic injury
during and/or after ECMO therapy is still unclear.
Recent research reported that imbalance of immune in-










vels of S100B and NSE were assessed 0, 2 6, 12 and 24 hour’s ECMO
senting the S100B and NSE mean concentrations with SD.
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posure to foreign surface of ECMO circuit, blood flow
shear stress, expression of cytokine and activation of com-
plement system, abnormality of coagulation and fibrinolysis
system etc., neutrophils are activated, ultimately resulting in
the abnormal activation of systemic immune response
[12,21]. In this experiment, we also observed that the per-
ipheral serum pro-inflammatory cytokine TNF-α, IL-6 and
IL-1β concentrations were raised rapidly after two hours
during the ECMO treatment. And anti-inflammatory IL-10
presented a short term increase during the first two hours
of ECMO. However, it is uncertain whether ECMO treat-
ment can also lead to a peripheral immune inflammatory
response in cerebral tissues.
Lots of investigations confirmed that peripheral circu-
lating inflammatory cytokines such as TNF-a, IL-1β and
IL-6 can invade into the brain through perventricular organ
or transport mechanism of vascular endothelial cells
[22-24]. These cytokines can also recruit other inflamma-
tory mediators into brain tissue [25]. They can also injure
the blood–brain barrier (BBB) and increase the permeabi-
lity of BBB [24,26,27]. In our study, we found that after 24 h
ECMO treatment, all of the pro-inflammation and anti-
inflammation cytokine mRNA expressed were significantly
up-regulated in the hypothalamus, the hippocampus and
the cortex. The gene post-transcriptional levels of pro-
inflammation cytokine IL-1β, IL-6, TNF-a and anti-
inflammation cytokine IL-10 increased notably to different
levels in the hypothalamus, or/and the hippocampus and
the cortex. The results indicate that ECMO therapy can
lead to immune inflammatory response of brain tissue.
Mountains of studies show that cytokine manifest toxicity
on cerebral tissues. Brain ventricles or parenchyma injec-
tion of IL-1β may aggravate ischemic brain injury [28]. IL-1β
and TNF-a, which inject into the brain, can lead to abnor-
mal animal behavior [29]. Given IL-1β receptor antagonist
(IL-1RA) will reduce the brain injury and death of the
cranial nerves [30]. TNF-a and IL-1β can activate the
hypothalamic-pituitary-adrenal (HPA) axis, the autonomic
nervous system and the nucleus of neurons and glia, alter
the expression of neurotransmitters, affect the permeability
of cerebral blood vessels, and result in brain edema, brain
cells apoptosis and brain tissue remodeling [18,31-34].
To investigate the effect of immune inflammatory re-
sponse of cerebral tissues after ECMO therapy on neuro-
logical impairment, we measured the cerebral injury
specific biomarker S100B and NSE (Neuron -specific Eno-
lase) in serum [35,36]. S100B is most abundant in the glial
cells of the central nervous system (CNS), mainly in astro-
cytes. Neuron-specific Enolase are present almost exclu-
sively in the cytoplasm of neurons (γ–γ isoenzyme) and
neuroendocrine cells (α–γ isoenzyme). Our data showed
that ECMO treatment did not increase the concentrations
of S100 and NSE in serum. This indicates that althoughthe cerebral tissue appeared to develop immune inflam-
matory response during the ECMO procedure, it did not
result in notable neurological impairment.
Our experimental findings seem to be in contradiction
with the current studies (no significant neurological im-
pairment versus poor neurologic outcomes). The main
reasons include: first, in the study, the VV-ECMO bypass
method was used rather than the venoarterial (V-A)
ECMO method. Current studies believe the injuries were
observed mainly in patients treated with VA-ECMO
[10,11,37]. This is because in the VA-ECMO model ra-
ther than in the VV-ECMO model [11,37], the carotid
artery needs to be ligated and nonpulsatile flow gene-
rated in the brain, which results in loss of autoregulation,
hypoxia and ischemia in the brain. In addition, the blood
is returned directly into the artery in VA-ECMO. How-
ever, the lungs function as a filter in the VV-ECMO
model [11]. Secondly, in order to deplete the effect of the
disease itself on the experimental results, normal pig
model was used as the experiment subject. In other
words, the neurological impairment may be related to
the disease itself rather than to ECMO therapy. Thirdly,
the increasing extent of pro-inflammatory cytokines is
not sufficient to cause brain injury. At the same time,
the anti-inflammatory cytokine IL-10 also increased in
cerebral tissues. A number of studies confirmed that the
anti-inflammatory cytokine IL-10 has a significant pro-
tective effect on brain injury [38,39].
In this study, there are some limitations. First, to in-
vestigate the effect of ECMO technology on brain injury,
we used a normal pig model as the experiment subject.
Although it can rule out the effect of the disease itself
on the experimental results, it does not reflect the rela-
tionship of pathophysiological changes between various
diseases and ECMO treatment. Secondly, this study did
not check morphology alteration to determine brain in-
jury. Although S100B and NSE are specific biomarkers
for neurological injury, they cannot offer response to the
extent of cerebral tissue injury.
Conclusion
In conclusion, the results of our study showed VV-ECMO
treatment can not only lead to immune inflammatory re-
sponse in blood, but can also produce immune and in-
flammatory response in cerebral tissues. However the
extent of immune inflammation was not sufficient to
cause significant neurological impairment in this study.
But the correlation between cerebral inflammatory re-
sponse and cerebral impairment need to further explore.
The study results may provide a basis for the development
of treatment strategies for neurologic injury during and/or
ECMO therapy in clinical practice. And the results of this
study suggest that clinical ECMO treatment may need to
be used in conjunction with an anti-inflammation therapy.
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